Literature DB >> 30846497

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Vincent Ten Cate1, Anthonie W A Lensing2, Jeffrey I Weitz3, Jan Beyer-Westendorf4, Philip S Wells5, Patrick Mismetti6, Paolo Prandoni7, Alexander T Cohen8, Bruce L Davidson9, Martin H Prins10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30846497      PMCID： PMC6886408          DOI： 10.3324/haematol.2018.209924

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Venous thromboembolism: advances and controversies. Preface.

Authors:  Benjamin Brenner
Journal:  Best Pract Res Clin Haematol       Date:  2012-08-14       Impact factor: 3.020

2.  Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?

Authors:  Alex C Spyropoulos; Ron Preblick; Winghan J Kwong; Melissa Lingohr-Smith; Jay Lin
Journal:  Clin Appl Thromb Hemost       Date:  2016-11-30       Impact factor: 2.389

3.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

4.  The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease.

Authors:  M Stain; V Schönauer; E Minar; C Bialonczyk; M Hirschl; A Weltermann; P A Kyrle; S Eichinger
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

Review 5.  Hereditary thrombophilia and venous thromboembolism: critical evaluation of the clinical implications of screening.

Authors:  L Mazzolai; M A Duchosal
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-06-27       Impact factor: 7.069

6.  Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.

Authors:  Rupert M Bauersachs; Anthonie Wa Lensing; Martin H Prins; Dagmar Kubitza; Ákos F Pap; Hervé Decousus; Jan Beyer-Westendorf; Paolo Prandoni
Journal:  Thromb J       Date:  2014-11-24

Review 7.  Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Authors:  Alok A Khorana; Marc Carrier; David A Garcia; Agnes Y Y Lee
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

8.  Determinants of treatment duration in the prevention of recurrent venous thromboembolism: a protocol for a balanced vignette experiment.

Authors:  Vincent Ten Cate; Brigitte Ab Essers; Martin H Prins
Journal:  BMJ Open       Date:  2017-05-10       Impact factor: 2.692

Review 9.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17

10.  Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries.

Authors:  Vincent Ten Cate; Martin H Prins
Journal:  Res Pract Thromb Haemost       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.